11th Annual Discovery on Target
Venue: The Westin Boston Waterfront
|Event Date/Time: Sep 24, 2013||End Date/Time: Sep 26, 2013|
|Early Registration Date: Aug 16, 2013|
|Abstract Submission Date: Aug 16, 2013|
Produced by Cambridge Healthtech Institute (CHI), the 11th Annual International Drug Discovery on Target is the premier event showcasing current and emerging "hot" targets for the pharmaceutical industry. Spanning three days, the meeting attracts over 630+ attendees (from 24 countries), composed of scientists/technologists, executives, directors, and managers from biopharma, academic, and healthcare organizations. The meeting is comprised of 11 meeting tracks which include Targeting Epigenetic Readers; Targeting Histone Methyltransferases; Next Generation Histone Deacetylase Inhibitors; Targeting Histone Demethylases; GPCR-Based Drug Discovery; GPCR-Targeted Therapeutics; Functional Genomics Screening Strategies; Novel Strategies for Kinase Inhibitors; Antibodies against Membrane Protein Targets; and Cardio-Metabolic Drug Targets. The 2013 event will offer 150+ scientific presentations across these 11 conference tracks and 10 pre-conference short courses, 30+ interactive breakout discussion groups, an exhibit hall of 30+ companies, and dedicated poster viewing and networking sessions. The 11th Annual International Drug Discovery on Target assembles an impressive group of 175+ distinguished speakers who look forward to sharing their knowledge, best practices, and expertise with all attendees.
For a full list of speakers and presentations, please visit DiscoveryOnTarget.com.
Current exhibitors include:
- Albany Molecular Research
- BioAgilytix Labs
- Cayman Chemical CompanyCellecta, Inc.
- Cerep Inc.
- EMD Millipore
- Meso Scale Diagnostics, LLC
- Mirimus, Inc.
- Promega Corporation
- ProQinase GmbH
- Reaction Biology Corporation
- SB Drug Discovery
- Simulations Plus, Inc.